Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lynn Henry

Showing results (21-30 of 190) with videos related to

Pageof 19
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 17, 2023
Testing for <i>ESR1</i> Mutations to Guide Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: ASCO Guideline Rapid Recommendation UpdateHarold J Burstein, Angela DeMichele, Mark R Somerfield, et al.
Clinical and Translational Science|November 14, 2025
Pharmacokinetic-Pharmacodynamic Model of Paclitaxel-Induced Peripheral NeuropathyYuchen Sun, Manjunath P Pai, N Lynn Henry, et al.
Clinical Breast Cancer|April 19, 2023
Ovarian Function Suppression in Premenopausal Women With Concurrent Endocrine Therapy UseNicole M Grogan Fleege, Yajing Li, Kelley M Kidwell, et al.
Plos One|January 22, 2025
Self-acupressure for patients with breast cancer experiencing aromatase inhibitor-associated musculoskeletal symptoms: Protocol for the AcuAIM randomized pilot trialN Lynn Henry, Kelley M Kidwell, Stephanie Kozar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 13, 2024
Endocrine and Targeted Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer-Capivasertib-Fulvestrant: ASCO Rapid Recommendation UpdateHarold J Burstein, Angela DeMichele, Lesley Fallowfield, et al.
Nature Reviews. Cancer|October 13, 2006
Breast cancer treatment and ovarian failure: risk factors and emerging genetic determinantsVered Stearns, Bryan Schneider, N Lynn Henry, et al.
Breast Cancer Research and Treatment|January 23, 2016
Incidental radiologic findings at breast cancer diagnosis and likelihood of disease recurrenceJoel M Brothers, Kelley M Kidwell, Richard K J Brown, et al.
Clinical Pharmacology and Therapeutics|December 7, 2023
Risk of Toxicity From Topical 5-Fluorouracil Treatment in Patients Carrying DPYD Variant AllelesJavier Granados, Amy L Pasternak, N Lynn Henry, et al.
JCO Oncology Practice|March 3, 2022
Survey of US Medical Oncologists' Practices and Beliefs Regarding <i>DPYD</i> Testing Before Fluoropyrimidine ChemotherapyKyoin Koo, Amy L Pasternak, N Lynn Henry, et al.
Clinical Breast Cancer|February 28, 2025
Characterizing Cannabidiol Use in a Breast Cancer PopulationNicole M G Fleege, Bradley T Loeffler, Kevin F Boehnke, et al.
Pageof 19

Showing results (21-30 of 190) with videos related to

Sort By:
Pageof 19
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 17, 2023
Testing for <i>ESR1</i> Mutations to Guide Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: ASCO Guideline Rapid Recommendation UpdateHarold J Burstein, Angela DeMichele, Mark R Somerfield, et al.
Clinical and Translational Science|November 14, 2025
Pharmacokinetic-Pharmacodynamic Model of Paclitaxel-Induced Peripheral NeuropathyYuchen Sun, Manjunath P Pai, N Lynn Henry, et al.
Clinical Breast Cancer|April 19, 2023
Ovarian Function Suppression in Premenopausal Women With Concurrent Endocrine Therapy UseNicole M Grogan Fleege, Yajing Li, Kelley M Kidwell, et al.
Plos One|January 22, 2025
Self-acupressure for patients with breast cancer experiencing aromatase inhibitor-associated musculoskeletal symptoms: Protocol for the AcuAIM randomized pilot trialN Lynn Henry, Kelley M Kidwell, Stephanie Kozar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 13, 2024
Endocrine and Targeted Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer-Capivasertib-Fulvestrant: ASCO Rapid Recommendation UpdateHarold J Burstein, Angela DeMichele, Lesley Fallowfield, et al.
Nature Reviews. Cancer|October 13, 2006
Breast cancer treatment and ovarian failure: risk factors and emerging genetic determinantsVered Stearns, Bryan Schneider, N Lynn Henry, et al.
Breast Cancer Research and Treatment|January 23, 2016
Incidental radiologic findings at breast cancer diagnosis and likelihood of disease recurrenceJoel M Brothers, Kelley M Kidwell, Richard K J Brown, et al.
Clinical Pharmacology and Therapeutics|December 7, 2023
Risk of Toxicity From Topical 5-Fluorouracil Treatment in Patients Carrying DPYD Variant AllelesJavier Granados, Amy L Pasternak, N Lynn Henry, et al.
JCO Oncology Practice|March 3, 2022
Survey of US Medical Oncologists' Practices and Beliefs Regarding <i>DPYD</i> Testing Before Fluoropyrimidine ChemotherapyKyoin Koo, Amy L Pasternak, N Lynn Henry, et al.
Clinical Breast Cancer|February 28, 2025
Characterizing Cannabidiol Use in a Breast Cancer PopulationNicole M G Fleege, Bradley T Loeffler, Kevin F Boehnke, et al.
Pageof 19